Warner-lambert Company

Godecke Aktiengesellschaft

Goedecke Aktiengesellschaft

Gerhard Satzinger

Manfred F Herrmann

Johannes Hartenstein

Edgar Fritschi

Peter Johannes Stoss

Hartmut Osswald

Karl Mannhardt

Hubert G Barth

Wolfgang Dieter Herrmann

Karl-Otto Vollmer

Ute Weiershausen

Volker Ganser

Gustav Hechtfischer

Jurgen Kleinschroth

Wolfgang Steinbrecher

Gunter Weinheimer

Bernd Wagner

Wolf-Dieter Vigelius

Heinrich Bahrmann

Gunter Wolf

Wolfgang Heldt

Horst-Dietmar Tauschel

Gerd Bartoszyk

Ilse-Dore Schutt

Jorgen Kleinschroth

Wolfram Geibel

Wolfgang Heidt

Gonter Weinheimer

Hartenstein

Dieter Muster

Manfred Hermann

The present invention provides a pharmaceutical composition containing 3,4-dihydro-1-phenyl-1-thio -1,2,4-benzothiadiazine 1-oxide useful for protecting lymphocytes.

Antiviral pharmaceutical composition for treating lymphocytes

The present invention provides substituted N-(2'-aminophenyl)-benzamide derivatives useful for combating neoplastic diseases. The present invention also provides a process for the preparation of these benzamide derivatives, as well as pharmaceutical compositions containing them and methods for using them.

N-(2'-aminophenyl)-benzamide derivatives process for the preparation

N-phenylbenzamide derivatives of the general formula I ##STR1## wherein the radicals R.sup.1, R.sup.2, and R.sup.3, which can be the same or different, are a hydrogen atom or a methyl radical, as well as the pharmacologically acceptable salts thereof for controlling refractory tumors in mammals are described.

N-phenylbenzamide derivatives

The use of benzothiazepine derivatives for the protection of lymphocytes in humans and higher mammals, especially in the treatment of acquired immune deficiency syndrome.

Use of benzothiazepine derivatives as lymphocyte protectors

N-phenylbenzamide derivatives of the general formula I ##STR1## wherein the radicals R.sup.1, R.sup.2, and R.sup.3, which can be the same or different, are a hydrogen atom or a methyl radical, as well as the pharmacologically acceptable salts thereof for controlling malignant, proliferative and auto-immune diseases and for immunosuppressive therapy upon grafting are described.

4-Alkoxy-pyrido[2,3-d]pyrimidine derivatives are described as well as processes for their preparation. For reason of their vasospasmolytic effects these compounds are mainly indicated for the treatment of cerebral, cardiac, and peripheral vascular diseases such as myocardiac ischemia, cerebral infarction, pulmonary thromboses, as well as in cases of arterioschlerosis and other stenotic disorders. They are therefore valuable agents for combating cardiovascular mortality.

4-alkoxy-pyrido[2,3-d]pyrimidine derivatives for treatment of myocardiac

The present invention describes 1,6-naphthyridine derivatives of the general formula: ##STR1## wherein R.sup.1 is an unsubstituted or substituted aromatic or heteroaromatic ring, R.sup.2 is a straight-chained or branched alkyl radical containing up to four carbon atoms or a benzyl radical, R.sup.3 is a hydrogen atom, a straight-chained or branched alkyl radicals or an alkoxycarbonyl radical containing up to four carbon atoms, R.sup.4 is a straight-chained or branched alkyl radical containing up to four carbons and R.sup.5 is a carboxyl group or a straight-chained, branched or cyclic alkoxycarbonyl radical which contains up to 17 carbon atoms and optionally also contains an oxygen, sulphur or nitrogen atom; as well as the pharmacologically acceptable salts thereof, which are useful for treating diseases of the blood vessels.

1,6-naphthyridine derivatives useful for treating diseases of the blood

The present invention provides 1,6-naphthyridine derivatives of formula ##STR1## wherein R.sup.1 is an unsubstituted or substituted aromatic or heteroaromatic ring or an unsubstituted or substituted condensed aromatic or heterocyclic ring system, R.sup.2 is a straight-chained or branched alkyl radical containing up to 4 carbon atoms, a benzyl radical or a straight-chained or branched, substituted or unsubstituted aminoalkyl radical containing up to 8 carbon atoms, R.sup.3 is a hydrogen atom, a straight-chained or branched alkyl radical or an alkoxycarbonyl radical, in each case containing up to 4 carbon atoms, R.sup.4 is a straight-chained or branched hydrocarbon radical containing up to 21 carbon atoms, which can also contain oxygen, sulphur, nitrogen or halogen atoms and is optionally substituted by carbocyclic or heterocyclic ring systems, or is an amino, cyano, formyl, halogenomethyl or dihalomethyl radical and R.sup.5 is an alkoxycarbonyl radical or an unsubstituted or substituted carboxamide radical with, in each case, up to 21 carbon atoms which can also contain oxygen, sulphur or nitrogen atoms and is optionally substituted by carbocyclic or heterocyclic ring systems or is a carboxyl or cyano group as well as the pharmaceutically acceptable salts thereof. The compounds are useful for blood vessel diseases. The present invention also provides processes for the preparation of these 1,6-naphthyridine derivatives, pharmaceutical compositions containing them, and methods for using them.

1,6-naphthyridine derivatives

The present invention provides combination of materials for strengthening the antithrombotic action of acetylsalicylic acid. It covers a composition which contains diltiazem or a pharmaceutically acceptable acid-addition salt thereof in combination with acetylsalicylic acid. It also forms the new compound diltiazem acetysalicylate. It also covers compositions containing the above and methods for using the compositions or compound.

Pharmaceutical composition with antithrombotic activity

New 1,6-naphthyridinone derivatives of the formula I ##STR1## are herein described wherein R.sup.1 represents an unsubstituted or substituted aromatic or heteroaromatic ring;

Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis

4-Alkoxy-pyrido[2,3-d]pyrimidine derivatives are described as well as processes for their preparation. For reason of their vasospasmolytic effects these compounds are mainly indicated for the treatment of cerebral, cardiac, and peripheral vascular diseases such as myocardiac ischemia, cerebral infarction, pulmonary thromboses, as well as in cases of arteriosclerosis and other stenotic disorders. They are therefore valuable agents for combating cardiovascular mortality.

4-alkoxy-pyrido[2,3-d]pyrimidine derivatives

4-Oxo-pyrido[2,3-d]pyrimidine derivatives are herein described as well as processes for their preparation. These compounds possess valuable pharmacological properties. As calcium antagonists they exert vasospasmolytic, vasodilatory, and antihypertensive activities. Surprisingly some of the compounds also have the effect of increasing contractility. They are therefore particularly suited for the treatment of vascular diseases.

4-oxo-pyrido[2,3-d]pyrimidinone derivatives

A process for the preparation of racemic asocainol in the (R,R; S,S)-form and (-)-asocainol in the (S,S)-form as well as the pharmacologically compatible salts thereof is herein described on the basis of a thermal rearrangement of the inactive (R,S)-diastereomer to the (S,S)-form. Racemic (.+-.)-asocainol and the (-)-enantiomer are potent antiarrhythmic agents and local anesthetics.

Process for the manufacture of racemic (R,R; S,S) asocainol

The invention is concerned with partially new compounds of the general formula ##STR1## wherein R.sup.1 is a hydrogen atom or an alkyl group with up to four carbon atoms and R.sup.2 a substituted phenyl radical and the pharmacologically acceptable salts thereof. The compounds can be prepared according to known procedures and show surprisingly a cardiovascular efficacy. They are capable of decompensating cardiac insufficiencies to a large extent. In addition to the new compounds, claim is also made for pharmaceutical compositions which contain compounds according to the general formula and their application for controlling cardiac and vascular diseases.

Growing community of inventors

Denzlingen, Germany

Gerhard Satzinger